(MENAFN- EIN Presswire)
U.S. viral Vector And Plasmid DNA manufacturing Market
The surge in genetic disorders and contaminated illnesses has demanded the usage of viral vectors for remedial motives.
The market is observing growth due to escalated government funding.” - Polaris Market ResearchNEW YORK CITY, NY, UNITED STATES, September 20, 2024 /EINPresswire / -- The U.S. viral vector and plasmid DNA manufacturing market report assesses the competitive scenario of the market, examining all the established players and new market entrants.
The market for U.S. viral vector and plasmid DNA manufacturing market is expanding. The market, valued at USD 2,204.51 million in 2023, is poised to reach USD 11,315.21 million by 2032. It is anticipated to register a CAGR of 19.9% from 2024 to 2032.
Market Introduction:
Viral vector manufacturing is the procedure essential for generating the important bearers that convey remedial genes. They are broadly utilized in areas such as gene therapy, rendering their maximized manufacturing important in the biopharma industry. At its nucleus, viral vector manufacturing spins around choosing appropriate producer cell lines maximizing the production procedure and abiding by stringent regulatory levels as well as present Good Manufacturing Practices. These measures are important to assure elevated levels of security and potency in the ultimate gene therapy commodities.
Host cell lines perform an important part in manufacturing viral vectors, impacting production organization and commodity standards. These cells behave as factories where viral vectors are made rendering the choosing of the appropriate host cell lines, an important settlement in manufacturing procedure. Normally only a handful of entrenched host cell lines have been the favoured alternative in viral vector manufacturing. One of these is HEK293 acknowledged for being effortless to evolve and producing adequate vectors. The escalated incidence of earmarked illnesses such as spinal muscular atrophy is influencing the U.S. viral vector and plasmid DNA manufacturing demand favourably.
Download Free Sample PDF Copy of the Report:
/request-for-sample
Key Report Highlights:
.The U.S. viral vector and plasmid DNA manufacturing market size was valued at USD 2,204.51 million in 2023 and is projected to grow to USD 11,315.21 million by 2032.
.An escalating aggregate of clinical trials and accepted gene remedies has caused an escalated demand for viral vectors.
.The market segmentation is primarily based on vector type, disease, workflow, application, and end-use.
Competitive Landscape:
The U.S. viral vector and plasmid DNA manufacturing market is characterized by competitiveness. The top market participants such as Bio-Rad Laboratories, Inc., Catalent Inc., Charles River Laboratories (Cobra Biologics), Genezen, Promega Corporation, RegenxBio, Inc., Revvity (SIRION Biotech), Thermo Fisher Scientific, Inc., Virovek Incorporation and Waisman Biomanufacturing concentrate on committing a plethora of strategic ventures to augment their footprint with crucial market advancements. Here are some of the major market developments:
.In January 2024, Charles River Laboratories International, Inc. instigated its off-the-shelf Rep/Cap plasmid benefaction, which targets simplifying AAV-dependent gene therapy initiatives.
.In August 2022, Thermo Fisher Scientific Inc. augmented its viral vector assembling potential in Plainville, Massachusetts. This augmentation objects to support the potential for testing, advancement, and extensive manufacturing of viral vectors, basically easing the commercialization and progression of gene remedy applications.
Growth Drivers and Opportunities:
Growing Existence of Cancer: The growing existence of cancer has pushed the demand for progressive and productive cancer cures, causing an escalating requirement for viral vectors and plasmid DNA. Therefore, there is an anticipated surge in the U.S. viral vector and plasmid DNA manufacturing market share as research and development endeavors classify the advancement of these important constituents for cancer cures.
Growing Cases of Genetic Disorders: The growing instances of genetic disorders and cancer have caused a rise in the demand for inventive cures, especially gene and cell therapies. These therapies massively rely on viral vectors for the productive conveyance of genetic substances to earmark cells.
Technological Progressions: The market is encountering speedy development by technological progressions and the initiation of contemporary technologies. These advancements are improving the regulation, scalability, and standard of manufacturing procedures, permitting the creation of elevated standard vectors important for gene and cell remedies.
Request for a Discount on this Report Before Purchase:
/request-for-discount-pricing
Segmental Overview:
By Vector Type Outlook
.Adeno-associated virus (AAV)
.Adenovirus
.Lentivirus
.Others
.Plasmids
.Retrovirus
By Disease Outlook
.Cancer
.Genetic Disorders
.Infectious Diseases
.Others
By Workflow Outlook
.Upstream Manufacturing
oVector Amplification & Expansion
oVector Recovery/Harvesting
.Downstream Manufacturing
oFill Finish
oPurification
By Application Outlook
.Antisense & RNAi Therapy
.Cell Therapy
.Gene Therapy
.Research Applications
.Vaccinology
By End-Use Outlook
.Pharmaceutical and Biopharmaceutical Companies
.Research Institutes
Inquire more about this report before purchase:
/inquire-before-buying
FAQs:
How much is the U.S. viral vector and plasmid DNA manufacturing market worth?
The market size was valued at USD 2,204.51 million in 2023.
What is the growth rate of the U.S. viral vector and plasmid DNA manufacturing market?
The market is projected to grow at a CAGR of 19.9% during the forecast period 2024-2032.
Who are the key players in the market?
The key players in the market are Bio-Rad Laboratories, Inc., Catalent Inc., Charles River Laboratories (Cobra Biologics), Genezen, Promega Corporation, RegenxBio, Inc., Revvity (SIRION Biotech), Thermo Fisher Scientific, Inc., Virovek Incorporation, and Waisman Biomanufacturing.
Which disease led the market?
The cancer category dominated the market in 2023.
Which end-use had the fastest market growth?
The pharmaceutical and biopharmaceutical companies had the fastest growth in the market.
Browse More Research Reports:
Addiction Treatment Market
Apheresis Equipment Market
Cancer Pain Management Market
Diabetes Device Market
Multiple Sclerosis Market
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
Likhil G
Polaris Market Research and Consulting
+1 929-297-9727
...
Visit us on social media:
Facebook
X
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN20092024003118003196ID1108696783